DDInter484 DDInter1147
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Dasatinib {u} (Compound) binds {v} (Gene) SRC
Dasatinib {u} (Compound) upregulates {v} (Gene) SATB1
Dasatinib {u} (Compound) downregulates {v} (Gene) EBNA1BP2
Dasatinib {u} (Compound) causes {v} (Side Effect) Body temperature increased
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Granisetron
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Dasatinib (Compound) treats hematologic cancer (Disease)
Dasatinib (Compound) binds SRC (Gene)
Dasatinib (Compound) upregulates SATB1 (Gene)
Dasatinib (Compound) downregulates EBNA1BP2 (Gene)
Dasatinib (Compound) causes Body temperature increased (Side Effect)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Dasatinib may lead to a major life threatening interaction when taken with Halofantrine